FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, has been selected to participate in Innovate UK's Global Business Innovation Programme (GBIP) focusing on Antimicrobial Resistance.
This year, FluoretiQ will join a delegation representing cutting-edge UK diagnostics, therapeutics, preventatives, and vaccines, headed to Switzerland.
Innovate UK's GBIP supports innovative SMEs in exploring global markets to accelerate business growth. Each GBIP, tailored to specific markets and technology sectors, includes up to 15 ambitious UK businesses looking to expand globally. The program aims to help these businesses explore future opportunities and understand what it takes to succeed on the global stage.
GBIP offers detailed market knowledge, cultural insight, and valuable introductions and connections, opening doors that SMEs might struggle to access independently. Each business is supported by an Innovate UK EDGE innovation and growth specialist to maximize the program's potential and beyond.
FluoretiQ Ltd, born at the Quantum Technology Enterprise Centre (QTEC) in Bristol, envisions revolutionizing bacteria identification. Their innovation—a rapid and straightforward bacteria diagnostic test—utilizes innovative probes and powerful fluorescence sensors to detect and identify bacteria in physiological samples.
- October 2024 (4)
- September 2024 (4)
- August 2024 (4)
- July 2024 (1)
- June 2024 (3)
- May 2024 (2)
- April 2024 (2)
- March 2024 (3)
- February 2024 (8)
- January 2024 (7)
- December 2023 (1)
- November 2023 (7)
- October 2023 (6)
- September 2023 (4)
- August 2023 (4)
- July 2023 (7)
- June 2023 (5)
- May 2023 (3)